|
1
|
Lu D, Chen S, Tan X, Li N, Liu C, Li Z,
Liu Z, Stupack DG, Reisfeld RA and Xiang R: Fra-1 promotes breast
cancer chemo-sensitivity by driving cancer stem cells from
dormancy. Cancer Res. 72:3451–3456. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Adiseshaiah P, Lindner DJ, Kalvakolanu DV
and Reddy SP: FRA-1 proto-oncogene induces lung epithelial cell
invasion and anchorage-independent growth in vitro, but is
insufficient to promote tumor growth in vivo. Cancer Res.
67:6204–6211. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Young MR and Colburn NH: Fra-1 a target
for cancer prevention or intervention. Gene. 379:1–11. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xiao S, Zhou Y, Yi W, Luo G, Jiang B, Tian
Q, Li Y and Xue M: Fra-1 is downregulated in cervical cancer
tissues and promotes cervical cancer cell apoptosis by p53
signaling pathway in vitro. Int J Oncol. 46:1677–1684.
2015.PubMed/NCBI
|
|
5
|
Liu H, Ren G, Wang T, Chen Y, Gong C, Bai
Y, Wang B, Qi H, Shen J, Zhu L, et al: Aberrantly expressed Fra-1
by IL-6/STAT3 transactivation promotes colorectal cancer
aggressiveness through epithelial-mesenchymal transition.
Carcinogenesis. 36:459–468. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang HL, Wang J, Xiao SY, Haydon R,
Stoiber D, He TC, Bissonnette M and Hart J: Elevated protein
expression of cyclin D1 and Fra-1 but decreased expression of c-Myc
in human colorectal adenocarcinomas overexpressing beta-catenin.
Int J Cancer. 101:301–310. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Oliveira-Ferrer L, Kürschner M, Labitzky
V, Wicklein D, Müller V, Lüers G, Schumacher U, Milde-Langosch K
and Schröder C: Prognostic impact of transcription factor Fra-1 in
ER-positive breast cancer: Contribution to a metastatic phenotype
through modulation of tumor cell adhesive properties. J Cancer Res
Clin Oncol. Feb 10–2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Belguise K, Milord S, Galtier F,
Moquet-Torcy G, Piechaczyk M and Chalbos D: The PKCθ pathway
participates in the aberrant accumulation of Fra-1 protein in
invasive ER-negative breast cancer cells. Oncogene. 31:4889–4897.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Davis WJ, Lehmann PZ and Li W: Nuclear
PI3K signaling in cell growth and tumorigenesis. Front Cell Dev
Biol. 3:242015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brown KK and Toker A: The phosphoinositide
3-kinase pathway and therapy resistance in cancer. F1000Prime Rep.
7:132015. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zheng D, Zhu G, Liao S, Yi W, Luo G, He J,
Pei Z, Li G and Zhou Y: Dysregulation of the PI3K/Akt signaling
pathway affects cell cycle and apoptosis of side population cells
in naso-pharyngeal carcinoma. Oncol Lett. 10:182–188.
2015.PubMed/NCBI
|
|
12
|
Liao S, Xiao S, Zhu G, Zheng D, He J, Pei
Z, Li G and Zhou Y: CD38 is highly expressed and affects the
PI3K/Akt signaling pathway in cervical cancer. Oncol Rep.
32:2703–2709. 2014.PubMed/NCBI
|
|
13
|
Saha T, Kar RK and Sa G: Structural and
sequential context of p53: A review of experimental and theoretical
evidence. Prog Biophys Mol Biol. 117:250–263. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Meng X, Franklin DA, Dong J and Zhang Y:
MDM2-p53 pathway in hepatocellular carcinoma. Cancer Res.
74:7161–7167. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Q, Zeng SX and Lu H: Targeting
p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem. 85:281–319.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Briest F and Grabowski P: The p53 network
as therapeutic target in gastroenteropancreatic neuroendocrine
neoplasms. Cancer Treat Rev. 41:423–430. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Abraham AG and O'Neill E:
PI3K/Akt-mediated regulation of p53 in cancer. Biochem Soc Trans.
42:798–803. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
19
|
Zhou Y, Wang W, Zheng D, Peng S, Xiong W,
Ma J, Zeng Z, Wu M, Zhou M, Xiang J, et al: Risk of nasopharyngeal
carcinoma associated with polymorphic lactotransferrin haplotypes.
Med Oncol. 29:1456–1462. 2012. View Article : Google Scholar
|
|
20
|
Zheng D, Liao S, Zhu G, Luo G, Xiao S, He
J, Pei Z, Li G and Zhou Y: CD38 is a putative functional marker for
side population cells in human nasopharyngeal carcinoma Cell Lines.
Mol Carcinog. Jan 28–2015.(Epub ahead of print). View Article : Google Scholar
|
|
21
|
Zhu W, Li J, Su J, Li J, Li J, Deng B, Shi
Q, Zhou Y and Chen X: FOS-like antigen 1 is highly expressed in
human psoriasis tissues and promotes the growth of HaCaT cells in
vitro. Mol Med Rep. 10:2489–2494. 2014.PubMed/NCBI
|
|
22
|
Hara A and Okayasu I: Cyclooxygenase-2 and
inducible nitric oxide synthase expression in human astrocytic
gliomas: Correlation with angiogenesis and prognostic significance.
Acta Neuropathol. 108:43–48. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Heo S, Spoerk S, Birner-Gruenberger R and
Lubec G: Gel-based mass spectrometric analysis of hippocampal
transmembrane proteins using high resolution LTQ Orbitrap Velos
Pro. Proteomics. 14:2084–2088. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Haddad T and Kümmerer K: Characterization
of photo-transformation products of the antibiotic drug
Ciprofloxacin with liquid chromatography-tandem mass spectrometry
in combination with accurate mass determination using an
LTQ-Orbitrap. Chemosphere. 115:40–46. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang JY, Wang F, Zhang H, Lu JQ and Qiao
YJ: Rapid identification of polymethoxylated flavonoids in
traditional Chinese medicines with a practical strategy of stepwise
mass defect filtering coupled to diagnostic product ions analysis
based on a hybrid LTQ-Orbitrap mass spectrometer. Phytochem Anal.
25:405–414. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Carcas LP: Gastric cancer review. J
Carcinog. 13:142014. View Article : Google Scholar
|
|
27
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Choi B, Lee EJ, Park YS, Kim SM, Kim EY,
Song Y, Kang SW, Rhu MH and Chang EJ: Pentraxin-3 silencing
suppresses gastric cancer-related inflammation by inhibiting
chemotactic migration of macrophages. Anticancer Res. 35:2663–2668.
2015.PubMed/NCBI
|
|
29
|
Saavedra K, Valbuena J, Olivares W,
Marchant MJ, Rodríguez A, Torres-Estay V, Carrasco-Avino G, Guzmán
L, Aguayo F, Roa JC, et al: Loss of expression of reprimo, a
p53-induced cell cycle arrest gene, correlates with invasive stage
of tumor progression and p73 expression in gastric cancer. PLoS
One. 10:e01258342015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Praud D, Parpinel M, Serafini M, Bellocco
R, Tavani A, Lagiou P, La Vecchia C and Rossi M: Non-enzymatic
antioxidant capacity and risk of gastric cancer. Cancer Epidemiol.
39:340–345. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Belguise K, Kersual N, Galtier F and
Chalbos D: FRA-1 expression level regulates proliferation and
invasiveness of breast cancer cells. Oncogene. 24:1434–1444. 2005.
View Article : Google Scholar
|
|
32
|
Philips A, Teyssier C, Galtier F,
Rivier-Covas C, Rey JM, Rochefort H and Chalbos D: FRA-1 expression
level modulates regulation of activator protein-1 activity by
estradiol in breast cancer cells. Mol Endocrinol. 12:973–985. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shirsat NV and Shaikh SA: Overexpression
of the immediate early gene fra-1 inhibits proliferation, induces
apoptosis, and reduces tumourigenicity of c6 glioma cells. Exp Cell
Res. 291:91–100. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang S and Qi Q: MTSS1 suppresses cell
migration and invasion by targeting CTTN in glioblastoma. J
Neurooncol. 121:425–431. 2015. View Article : Google Scholar
|
|
35
|
Folio C, Zalacain M, Zandueta C, Ormazábal
C, Sierrasesúmaga L, San Julián M, de las Rivas J, Toledo G,
Lecanda F and Patiño-García A: Cortactin (CTTN) overexpression in
osteosarcoma correlates with advanced stage and reduced survival.
Cancer Biomark. 10:35–41. 2012.PubMed/NCBI
|
|
36
|
Luo ML, Shen XM, Zhang Y, Wei F, Xu X, Cai
Y, Zhang X, Sun YT, Zhan QM, Wu M, et al: Amplification and
overexpression of CTTN (EMS1) contribute to the metastasis of
esophageal squamous cell carcinoma by promoting cell migration and
anoikis resistance. Cancer Res. 66:11690–11699. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Qiao M, Sheng S and Pardee AB: Metastasis
and AKT activation. Cell Cycle. 7:2991–2996. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wagner EF and Nebreda AR: Signal
integration by JNK and p38 MAPK pathways in cancer development. Nat
Rev Cancer. 9:537–549. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chumakov PM: Function of the p53 gene:
Choice between life and death. Biochemistry (Mosc). 65:28–40.
2000.
|
|
41
|
Chipuk JE and Green DR: Dissecting
p53-dependent apoptosis. Cell Death Differ. 13:994–1002. 2006.
View Article : Google Scholar : PubMed/NCBI
|
